View ValuationDanaher 향후 성장Future 기준 점검 2/6Danaher (는) 각각 연간 19.9% 및 5.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 18.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.4% 로 예상됩니다.핵심 정보19.9%이익 성장률18.66%EPS 성장률Life Sciences 이익 성장20.2%매출 성장률5.5%향후 자기자본이익률11.44%애널리스트 커버리지Good마지막 업데이트21 May 2026최근 향후 성장 업데이트공시 • Oct 22Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter. For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets.모든 업데이트 보기Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • May 07Danaher Corporation announces Quarterly dividend, payable on July 31, 2026Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026.Buy Or Sell Opportunity • Mar 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.공시 • Mar 26Danaher Corporation, Annual General Meeting, May 05, 2026Danaher Corporation, Annual General Meeting, May 05, 2026.공시 • Mar 21Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026공시 • Feb 25Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.공시 • Feb 17+ 1 more updateDanaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion.Danaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion on February 16, 2026. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings. In case of termination Masimo will pay $305 million. Danaher expects to fund the acquisition using cash on hand and proceeds from debt financing. The Transaction has been unanimously approved by both Masimo’s Board of Directors and Danaher’s Board of Directors and is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals, Masimo shareholders approval, HSR act approval. The merger is expected to close in the second half of 2026. Masimo is expected to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion of the acquisition. Centerview Partners LLC acted as financial advisor for Masimo Corporation. Morgan Stanley & Co. LLC acted as financial advisor for Masimo Corporation. Lauren S. Boehmke and Melissa Sawyer of Sullivan & Cromwell LLP acted as legal advisor for Masimo Corporation. Matthew Barnett and Richard Brand of White & Case LLP acted as legal advisor for Masimo Corporation. David M. Klein, Daniel E. Wolf, Adam Petravicius, Joanna Schlingbaum, Ellisen Shelton Turner, Jordan D. Peterson, Scott D. Price, David G. Branham, Maddison M. Riddick, Rachael L. Lichman, Joshua N. Korff, Diahndra Burman, Liam N. Murphy and Dean S. Shulman of Kirkland & Ellis LLP acted as legal advisor for Danaher Corporation. Longacre Square Partners acted as strategy and communications advisor to Masimo. Citigroup Inc. (NYSE:C) acted as financial advisor to Danaher Corporation.공시 • Feb 11Danaher Corporation Announces Retirement of Director, Jessica L. Mega, Effective February 5, 2026Danaher Corporation announced that Jessica L. Mega notified the Board of Directors of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega's decision was not the result of any disagreement with Danaher on any matter relating to Danaher's operations, policies or practices.Reported Earnings • Jan 29Full year 2025 earnings released: EPS: US$5.05 (vs US$5.33 in FY 2024)Full year 2025 results: EPS: US$5.05 (down from US$5.33 in FY 2024). Revenue: US$24.6b (up 2.9% from FY 2024). Net income: US$3.60b (down 7.7% from FY 2024). Profit margin: 15% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공시 • Dec 17Danaher Corporation to Report Q4, 2025 Results on Jan 28, 2026Danaher Corporation announced that they will report Q4, 2025 results at 6:00 AM, US Eastern Standard Time on Jan 28, 2026Declared Dividend • Dec 12Dividend of US$0.32 announcedShareholders will receive a dividend of US$0.32. Ex-date: 23rd December 2025 Payment date: 30th January 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 25%. Cash payout ratio: 18%.공시 • Dec 10Danaher Corporation Announces Quarterly Dividend, Payable on January 30, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025.Recent Insider Transactions • Nov 27Co-Founder & Director recently sold €8.1m worth of stockOn the 25th of November, Mitchell Rales sold around 41k shares on-market at roughly €199 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €203m.Recent Insider Transactions • Nov 14Co-Founder & Director recently sold €82m worth of stockOn the 12th of November, Mitchell Rales sold around 437k shares on-market at roughly €189 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €195m.공시 • Nov 08Danaher Corporation Announces Retirement of John T. Schwieters from Its BoardDanaher Corporation announced on November 6, 2025, John T. Schwieters notified the company’s Board of Directors that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting. Mr. Schwieters’ decision was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The size of the Board will be reduced from thirteen to twelve members as of the time of Mr. Schwieters’ retirement.Recent Insider Transactions • Nov 05Co-Founder & Director recently sold €112m worth of stockOn the 31st of October, Mitchell Rales sold around 600k shares on-market at roughly €187 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Mitchell's only on-market trade for the last 12 months.Reported Earnings • Oct 27Third quarter 2025 earnings released: EPS: US$1.28 (vs US$1.13 in 3Q 2024)Third quarter 2025 results: EPS: US$1.28 (up from US$1.13 in 3Q 2024). Revenue: US$6.05b (up 4.4% from 3Q 2024). Net income: US$908.0m (up 11% from 3Q 2024). Profit margin: 15% (in line with 3Q 2024). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공시 • Oct 22Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter. For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets.공시 • Sep 24Danaher Corporation to Report Q3, 2025 Results on Oct 21, 2025Danaher Corporation announced that they will report Q3, 2025 results at 6:00 AM, Eastern Standard Time on Oct 21, 2025공시 • Sep 10Danaher Announces Quarterly Dividend, Payable on October 31, 2025Danaher Corporation has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025.공시 • Aug 01Danaher Corporation Announces Executive ChangesDanaher Corporation announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. Prior to joining Danaher, Mr. Leiken served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Dollar Tree Inc., a Fortune 150 company, where he oversaw corporate governance, ethics and compliance, sustainability and regulatory affairs. Prior to that, he held the same role at Diebold Nixdorf Inc., a global technology company, where he also led intellectual property, internal audit and ESG functions. Mr. Leiken's career includes serving as a federal prosecutor in the U.S. Attorney's Office for the Southern District of New York, where he was recognized for superior performance by multiple federal agencies. He has also been a partner at a global law firm, advising Fortune 500 companies and major institutions on complex litigation, corporate strategy and regulatory matters. He holds a J.D., cum laude, from the University of Pennsylvania Law School and a B.A. in Political Science, magna cum laude, from Brandeis University.공시 • Jul 22Danaher Corporation Announces Chief Financial Officer Changes, Effective February 28 , 2026Danaher Corporation announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher. Mr. McGrew has served as Danaher's CFO since January 2019. He joined Danaher in 2004 as Director, M&A Finance and served in roles of increasing responsibility including Vice President, Investor Relations from 2009 to 2014 and as a Danaher Group CFO from 2012 to 2018. During his tenure as CFO, Danaher meaningfully increased its growth and margin profile, and nearly doubled both its revenue and market capitalization. Mr. Gugino joined Danaher in 2013 as Director, Investor Relations and served as Vice President, Investor Relations from 2014 to 2022. He has served as Vice President of Financial Planning & Analysis since 2019 and additionally as Group Chief Financial Officer in the Company's Life Sciences Innovations Group since 2021. Prior to joining Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley, and an Associate at KPMG. He holds a Bachelor of Science degree in Accounting and a Master of Accountancy and Professional Consultancy from Villanova University.공시 • Jun 28Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 IndexDanaher Corporation(NYSE:DHR) dropped from Russell Top 50 Index공시 • Jun 27+ 1 more updateDanaher Corporation Appoints Greg Milosevich to Executive Vice President, Life Sciences Business, Effective July 1, 2025Danaher Corporation announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. Mr. Milosevich joined Danaher in 2010, through the acquisition of Molecular Devices, and since has held roles of increasing responsibility across multiple businesses. In his most recent role, as Vice President and Group Executive, Life Sciences Innovations Group, Mr. Milosevich oversaw multiple Danaher companies, including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a bachelor's degree in physics from the University of Puget Sound, graduating Summa Cum Laude.공시 • Jun 18Danaher Corporation to Report Q2, 2025 Results on Jul 22, 2025Danaher Corporation announced that they will report Q2, 2025 results at 6:00 AM, US Eastern Standard Time on Jul 22, 2025공시 • May 07Danaher Announces Regular Quarterly Dividend, Payable on July 25, 2025Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €157, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share.Buy Or Sell Opportunity • Apr 05Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to €171. The fair value is estimated to be €220, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.6% over the last 3 years. Earnings per share has declined by 19%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.공시 • Mar 28Danaher Corporation, Annual General Meeting, May 06, 2025Danaher Corporation, Annual General Meeting, May 06, 2025.이익 및 매출 성장 예측BIT:1DHR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202828,8506,5206,8888,0661512/31/202726,9915,7526,1357,4322212/31/202625,4714,5355,6626,750223/27/202624,7783,6755,2916,439N/A12/31/202524,5683,6005,2606,416N/A9/26/202524,2683,5035,0176,318N/A6/27/202524,0133,4134,8626,169N/A3/28/202523,8203,7654,9026,248N/A12/31/202423,8753,8995,2966,688N/A9/27/202423,7423,9344,9786,288N/A6/28/202423,5684,0565,0816,447N/A3/29/202423,7374,0695,5486,956N/A12/31/202323,8904,2005,7817,164N/A9/29/202321,0264,4086,8428,086N/A6/30/202323,0655,0197,2578,424N/A3/31/202324,9045,7577,3648,498N/A12/31/202226,6436,2227,4018,519N/A9/30/202231,2506,6407,0688,311N/A7/1/202230,8166,2067,0518,335N/A4/1/202230,2836,2067,1628,455N/A12/31/202124,8025,2837,1188,358N/A10/1/202128,0655,6367,0568,246N/A7/2/202126,7205,3616,8767,935N/A4/2/202124,7994,5956,3517,260N/A12/31/202022,2843,5105,4176,208N/A10/2/202020,3923,0834,4445,099N/A7/3/202018,8862,8533,7124,341N/A4/3/202018,0342,6143,4394,068N/A12/31/201917,9112,364N/A3,952N/A9/27/201915,5622,093N/A4,078N/A6/28/201916,0372,145N/A4,032N/A3/29/201916,5732,166N/A3,896N/A12/31/201817,0492,406N/A4,022N/A9/28/201819,6152,761N/A3,619N/A6/29/201819,2902,669N/A3,772N/A3/30/201818,8192,553N/A3,747N/A12/31/201715,5192,172N/A3,478N/A9/29/201717,8282,360N/A3,292N/A6/30/201717,4322,191N/A3,038N/A3/31/201717,1642,051N/A3,309N/A12/31/201616,8822,153N/A3,522N/A9/30/201616,6211,927N/A4,104N/A7/1/201616,0011,905N/A4,239N/A4/1/201613,6631,775N/A4,051N/A12/31/201514,4341,747N/A3,802N/A10/2/201515,3351,875N/A3,810N/A7/3/201516,5302,177N/A3,873N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1DHR 의 연간 예상 수익 증가율(19.9%)이 saving rate(3.3%)보다 높습니다.수익 vs 시장: 1DHR 의 연간 수익(19.9%)이 Italian 시장(11%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 1DHR 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 1DHR 의 수익(연간 5.5%)이 Italian 시장(연간 5.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 1DHR 의 수익(연간 5.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1DHR의 자본 수익률은 3년 후 11.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 05:34종가2026/05/21 00:00수익2026/03/27연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Danaher Corporation는 44명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관John EadeArgus Research CompanyCatherine Ramsey SchulteBairdLuke SergottBarclays41명의 분석가 더 보기
공시 • Oct 22Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter. For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • May 07Danaher Corporation announces Quarterly dividend, payable on July 31, 2026Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026.
Buy Or Sell Opportunity • Mar 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
공시 • Mar 26Danaher Corporation, Annual General Meeting, May 05, 2026Danaher Corporation, Annual General Meeting, May 05, 2026.
공시 • Mar 21Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026
공시 • Feb 25Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.
공시 • Feb 17+ 1 more updateDanaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion.Danaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion on February 16, 2026. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings. In case of termination Masimo will pay $305 million. Danaher expects to fund the acquisition using cash on hand and proceeds from debt financing. The Transaction has been unanimously approved by both Masimo’s Board of Directors and Danaher’s Board of Directors and is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals, Masimo shareholders approval, HSR act approval. The merger is expected to close in the second half of 2026. Masimo is expected to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion of the acquisition. Centerview Partners LLC acted as financial advisor for Masimo Corporation. Morgan Stanley & Co. LLC acted as financial advisor for Masimo Corporation. Lauren S. Boehmke and Melissa Sawyer of Sullivan & Cromwell LLP acted as legal advisor for Masimo Corporation. Matthew Barnett and Richard Brand of White & Case LLP acted as legal advisor for Masimo Corporation. David M. Klein, Daniel E. Wolf, Adam Petravicius, Joanna Schlingbaum, Ellisen Shelton Turner, Jordan D. Peterson, Scott D. Price, David G. Branham, Maddison M. Riddick, Rachael L. Lichman, Joshua N. Korff, Diahndra Burman, Liam N. Murphy and Dean S. Shulman of Kirkland & Ellis LLP acted as legal advisor for Danaher Corporation. Longacre Square Partners acted as strategy and communications advisor to Masimo. Citigroup Inc. (NYSE:C) acted as financial advisor to Danaher Corporation.
공시 • Feb 11Danaher Corporation Announces Retirement of Director, Jessica L. Mega, Effective February 5, 2026Danaher Corporation announced that Jessica L. Mega notified the Board of Directors of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega's decision was not the result of any disagreement with Danaher on any matter relating to Danaher's operations, policies or practices.
Reported Earnings • Jan 29Full year 2025 earnings released: EPS: US$5.05 (vs US$5.33 in FY 2024)Full year 2025 results: EPS: US$5.05 (down from US$5.33 in FY 2024). Revenue: US$24.6b (up 2.9% from FY 2024). Net income: US$3.60b (down 7.7% from FY 2024). Profit margin: 15% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공시 • Dec 17Danaher Corporation to Report Q4, 2025 Results on Jan 28, 2026Danaher Corporation announced that they will report Q4, 2025 results at 6:00 AM, US Eastern Standard Time on Jan 28, 2026
Declared Dividend • Dec 12Dividend of US$0.32 announcedShareholders will receive a dividend of US$0.32. Ex-date: 23rd December 2025 Payment date: 30th January 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 25%. Cash payout ratio: 18%.
공시 • Dec 10Danaher Corporation Announces Quarterly Dividend, Payable on January 30, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025.
Recent Insider Transactions • Nov 27Co-Founder & Director recently sold €8.1m worth of stockOn the 25th of November, Mitchell Rales sold around 41k shares on-market at roughly €199 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €203m.
Recent Insider Transactions • Nov 14Co-Founder & Director recently sold €82m worth of stockOn the 12th of November, Mitchell Rales sold around 437k shares on-market at roughly €189 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €195m.
공시 • Nov 08Danaher Corporation Announces Retirement of John T. Schwieters from Its BoardDanaher Corporation announced on November 6, 2025, John T. Schwieters notified the company’s Board of Directors that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting. Mr. Schwieters’ decision was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The size of the Board will be reduced from thirteen to twelve members as of the time of Mr. Schwieters’ retirement.
Recent Insider Transactions • Nov 05Co-Founder & Director recently sold €112m worth of stockOn the 31st of October, Mitchell Rales sold around 600k shares on-market at roughly €187 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Mitchell's only on-market trade for the last 12 months.
Reported Earnings • Oct 27Third quarter 2025 earnings released: EPS: US$1.28 (vs US$1.13 in 3Q 2024)Third quarter 2025 results: EPS: US$1.28 (up from US$1.13 in 3Q 2024). Revenue: US$6.05b (up 4.4% from 3Q 2024). Net income: US$908.0m (up 11% from 3Q 2024). Profit margin: 15% (in line with 3Q 2024). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공시 • Oct 22Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter. For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets.
공시 • Sep 24Danaher Corporation to Report Q3, 2025 Results on Oct 21, 2025Danaher Corporation announced that they will report Q3, 2025 results at 6:00 AM, Eastern Standard Time on Oct 21, 2025
공시 • Sep 10Danaher Announces Quarterly Dividend, Payable on October 31, 2025Danaher Corporation has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025.
공시 • Aug 01Danaher Corporation Announces Executive ChangesDanaher Corporation announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. Prior to joining Danaher, Mr. Leiken served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Dollar Tree Inc., a Fortune 150 company, where he oversaw corporate governance, ethics and compliance, sustainability and regulatory affairs. Prior to that, he held the same role at Diebold Nixdorf Inc., a global technology company, where he also led intellectual property, internal audit and ESG functions. Mr. Leiken's career includes serving as a federal prosecutor in the U.S. Attorney's Office for the Southern District of New York, where he was recognized for superior performance by multiple federal agencies. He has also been a partner at a global law firm, advising Fortune 500 companies and major institutions on complex litigation, corporate strategy and regulatory matters. He holds a J.D., cum laude, from the University of Pennsylvania Law School and a B.A. in Political Science, magna cum laude, from Brandeis University.
공시 • Jul 22Danaher Corporation Announces Chief Financial Officer Changes, Effective February 28 , 2026Danaher Corporation announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher. Mr. McGrew has served as Danaher's CFO since January 2019. He joined Danaher in 2004 as Director, M&A Finance and served in roles of increasing responsibility including Vice President, Investor Relations from 2009 to 2014 and as a Danaher Group CFO from 2012 to 2018. During his tenure as CFO, Danaher meaningfully increased its growth and margin profile, and nearly doubled both its revenue and market capitalization. Mr. Gugino joined Danaher in 2013 as Director, Investor Relations and served as Vice President, Investor Relations from 2014 to 2022. He has served as Vice President of Financial Planning & Analysis since 2019 and additionally as Group Chief Financial Officer in the Company's Life Sciences Innovations Group since 2021. Prior to joining Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley, and an Associate at KPMG. He holds a Bachelor of Science degree in Accounting and a Master of Accountancy and Professional Consultancy from Villanova University.
공시 • Jun 28Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 IndexDanaher Corporation(NYSE:DHR) dropped from Russell Top 50 Index
공시 • Jun 27+ 1 more updateDanaher Corporation Appoints Greg Milosevich to Executive Vice President, Life Sciences Business, Effective July 1, 2025Danaher Corporation announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. Mr. Milosevich joined Danaher in 2010, through the acquisition of Molecular Devices, and since has held roles of increasing responsibility across multiple businesses. In his most recent role, as Vice President and Group Executive, Life Sciences Innovations Group, Mr. Milosevich oversaw multiple Danaher companies, including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a bachelor's degree in physics from the University of Puget Sound, graduating Summa Cum Laude.
공시 • Jun 18Danaher Corporation to Report Q2, 2025 Results on Jul 22, 2025Danaher Corporation announced that they will report Q2, 2025 results at 6:00 AM, US Eastern Standard Time on Jul 22, 2025
공시 • May 07Danaher Announces Regular Quarterly Dividend, Payable on July 25, 2025Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €157, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share.
Buy Or Sell Opportunity • Apr 05Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to €171. The fair value is estimated to be €220, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.6% over the last 3 years. Earnings per share has declined by 19%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
공시 • Mar 28Danaher Corporation, Annual General Meeting, May 06, 2025Danaher Corporation, Annual General Meeting, May 06, 2025.